Citigroup Inc T Scan Therapeutics, Inc. Call Options Transaction History
Citigroup Inc
- $217 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TCRX
# of Institutions
77Shares Held
37.5MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR7.86MShares$8.96 Million2.7% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$5.96 Million0.5% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$5.09 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$3.17 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.32MShares$2.64 Million0.0% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $21.6M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...